Abstract: A centrifugal reservoir pump for processing a hydrogen stream in an aircraft. In particular, a centrifugal reservoir pump including a pump casing, a hydrogen stream inlet, a rotor being rotatably arranged in the interior part of the pump and including rotor vanes for accelerating the hydrogen stream, and two hydrogen stream outlets. Further provided is a tank unit including the centrifugal reservoir pump and a reservoir for hydrogen. Further provided is an aircraft including a centrifugal reservoir pump or a tank unit. Further provided is a method of processing hydrogen in an aircraft.

Abstract: Phytosphingosine derivatives suitable as adjuvants in immune stimulation, pharmaceutical compositions comprising such compounds and the medical use of the compounds and/or compositions in therapeutic or prophylactic methods of immune stimulation in a subject, and for use in the treatment of a disease, for which stimulation of an immune response in a subject produces a therapeutic benefit. The phytosphingosine derivative may also be used as adjuvants in vaccinating a subject. The phytosphingosine derivative may also be used in stimulating antibody production, stimulating an immune response against infection, stimulating an immune response against a cancer, or preventing and/or treating septic shock. Methods for the manufacture of the derivatives comprising an Ugi-4-component reaction (Ugi-4CR) is also disclosed.

Abstract: An electrical arrangement on an aircraft fuselage has a fuselage component, an electrical consumer and a conductive electrical connection element. The connection element extends outwardly through an opening in the fuselage component and may have a bearing section on an inside or outside of the fuselage component that is arranged so as to tap or feed a voltage pole. The electrical connection element is electrically insulated from the opening and the fuselage component and is able to be connected to a voltage supply arranged on the inside. The electrical consumer is arranged on the outside of the fuselage component and is electrically connected to that part of the connection element projecting towards the outside of the fuselage.

Abstract: The present invention relates to a method for the diagnosis, prognosis, risk assessment, risk stratification, monitoring, therapy guidance and/or therapy control of cancer in a subject comprising the determination of the level of an anti-PD1 antibody and/or an anti-PD-L1 antibody in a sample of a bodily fluid of said subject.

Abstract: The invention relates to a method for diagnosis of an autoimmune disease in a subject wherein, presence or absence of an anti-CXC chemokine receptor (CXCR) antibody is detected in a sample from the subject diagnosed, and wherein the presence of an anti-CXCR antibody is indicative of the disease. The invention further relates to the use of (auto)antibodies against the C—X—C chemokine receptor type 3 (CXCR3) as a prognostic marker in subjects with acute graft-versus-host disease (GVHD), particularly in subjects with high grade acute GVHD. The invention also relates to the use of C—X—C chemokines selected from the group consisting of CXCL4, CXCL9, CXCL10 and CXCL11, preferably CXCL9, as a prognostic marker in subjects with acute GVHD, particularly in subjects with high grade acute GVHD.

Abstract: A monitoring system network has a plurality of sensor nodes with a sensor control device and at least one sensor element coupled to the sensor control device, a first hierarchical network layer with a plurality of network function nodes, each coupled to at least one of the plurality of sensor nodes, and a second hierarchical network layer with a plurality of network central nodes, each coupled to at least one of the plurality of network function nodes. The sensor control devices of the sensor nodes, the network function nodes and the network central nodes of the monitoring system network form a distributed system on which distributed applications can be performed for the evaluation of the sensor data signals captured by the sensor elements of the sensor nodes.

Abstract: A monitoring system network has a plurality of sensor nodes with a sensor control device and at least one sensor element coupled to the sensor control device, a first hierarchical network layer with a plurality of network function nodes, each coupled to at least one of the plurality of sensor nodes, and a second hierarchical network layer with a plurality of network central nodes, each coupled to at least one of the plurality of network function nodes. The sensor control devices of the sensor nodes, the network function nodes and the network central nodes, in each case, have a data processing device and a configuration memory which is coupled to the data processing device and designed to store configuration data for different configurations of the respective data processing device.

Abstract: The application relates to a method for diagnosis of a chronic fatigue disease, e.g. CFS or CRF, comprising the step of determining the presence or absence of antibodies directed against ?-adrenergic receptor in a sample of the subject to be diagnosed, wherein the presence of antibodies directed against ?-adrenergic receptor is indicative of the chronic fatigue disease in said subject. Furthermore, the application relates to kits comprising ?-adrenergic receptor or an antigenic peptide thereof and the use of ?-adrenergic receptor or an antigenic peptide thereof for the diagnosis of a chronic fatigue disease.

Abstract: An electrical arrangement on an aircraft fuselage has a fuselage component, an electrical consumer and a conductive electrical connection element. The connection element extends outwardly through an opening in the fuselage component and may have a bearing section on an inside or outside of the fuselage component that is arranged so as to tap or feed a voltage pole. The electrical connection element is electrically insulated from the opening and the fuselage component and is able to be connected to a voltage supply arranged on the inside. The electrical consumer is arranged on the outside of the fuselage component and is electrically connected to that part of the connection element projecting towards the outside of the fuselage.

Abstract: The present invention relates to a method for diagnosis of a cancer, comprising the steps of (i) determining the level of antibodies against epidermal growth factor receptor (EGFR) in a sample from a subject to be diagnosed, (ii) comparing the determined level in the sample to a control level derived from subjects without cancer; wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative for cancer in the subject. Furthermore, the invention relates to method of predicting response and outcome of a treatment of a cancer with an inhibitor of EGFR activity.

Abstract: The present invention relates to a method for diagnosis of a cancer, comprising the steps of (i) determining the level of antibodies against protease-activated receptor 1 (PAR1) in a sample from a subject to be diagnosed, (ii) comparing the determined level in the sample to a control level derived from subjects without ovarian cancer; wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative for ovarian cancer in the subject. Furthermore the invention relates to differential diagnosis of cancer and the prediction of the response of a subject to be treated for cancer with a drug.

Abstract: For the purification of waste gas containing carbon compounds and nitrogen oxides by means of a regenerative post-combustion system, at least two regenerators (A, B, C) filled with heat accumulator bodies (7a, 7b, 7c) and connected by a combustion chamber (10) are provided, wherein the waste gas is alternately heated in a regenerator (A, B, C), the carbon compounds are oxidised in the combustion chamber (10), and, with the addition of a nitrogen-hydrogen compound, the nitrogen oxides are reduced in the combustion chamber (10) thermally and thus not catalytically. Remaining nitrogen oxides are removed by means of a catalytically active heat accumulator layer (6a, 6b, 6c) and the addition of a further nitrogen-hydrogen compound in the regenerator (A, B, C) from which the clean gas exits.

Abstract: The present invention relates to a method for diagnosis of a cancer, comprising the steps of (i) determining the level of antibodies against vascular endothelial growth factor (VEGF) in a sample from a subject to be diagnosed, (ii) comparing the determined level in the sample to a control level derived from subjects without cancer; wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative for cancer in the subject. Furthermore, the invention relates to method of predicting response and outcome of a treatment of a cancer with an angiogenesis inhibitor.

Abstract: The present invention relates to a method for diagnosis of a cancer, comprising the steps of (i) determining the level of antibodies against epidermal growth factor (EGF) in a sample from a subject to be diagnosed, (ii) comparing the determined level in the sample to a control level derived from subjects without cancer; wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative for cancer in the subject. Furthermore, the invention relates to method of predicting response and outcome of a treatment of a cancer with an epidermal growth factor receptor inhibitor.

Abstract: The present invention relates to a method for diagnosis of a cancer, comprising the steps of (i) determining the level of antibodies against vascular endothelial growth factor receptor (VEGFR) in a sample from a subject to be diagnosed, (ii) comparing the determined level in the sample to a control level derived from subjects without cancer; wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative for cancer in the subject. Furthermore, the invention relates to method of predicting response and outcome of a treatment of a cancer with an angiogenesis inhibitor.

Abstract: The application relates to a method for diagnosis of an antiphospholipid syndrome (APS) in a subject, wherein presence or absence of an anti-protease-activated receptor 1 (PAR1) antibody is detected in a sample from the subject diagnosed, and wherein the presence of an anti-PAR1 antibody is indicative of the disease. Furthermore, it relates to the use of PAR1 for the diagnosis of APS, as well as to a method of removing anti-PAR1 antibodies from isolated blood of a subject upon detection of said anti-PAR1 antibodies in a sample of said patient.

Abstract: For the purification of waste gas containing carbon compounds and nitrogen oxides by means of a regenerative post-combustion system, at least two regenerators (A, B, C) filled with heat accumulator bodies (7a, 7b, 7c) and connected by a combustion chamber (10) are provided, wherein the waste gas is alternately heated in a regenerator (A, B, C), the carbon compounds are oxidised in the combustion chamber (10), and, with the addition of a nitrogen-hydrogen compound, the nitrogen oxides are reduced in the combustion chamber (10) thermally and thus not catalytically. Remaining nitrogen oxides are removed by means of a catalytically active heat accumulator layer (6a, 6b, 6c) and the addition of a further nitrogen-hydrogen compound in the regenerator (A, B, C) from which the clean gas exits.

Abstract: The application relates to a method for diagnosis of a chronic fatigue disease, e.g. CFS or CRF, comprising the step of determining the presence or absence of antibodies directed against ?-adrenergic receptor in a sample of the subject to be diagnosed, wherein the presence of antibodies directed against ?-adrenergic receptor is indicative of the chronic fatigue disease in said subject. Furthermore, the application relates to kits comprising ?-adrenergic receptor or an antigenic peptide thereof and the use of ?-adrenergic receptor or an antigenic peptide thereof for the diagnosis of a chronic fatigue disease.

Abstract: The application relates to a method for diagnosis of an autoimmune disease, comprising the step of determining the presence or absence of antibodies directed against CSa-receptor in a sample of the subject to be diagnosed, wherein the presence of antibodies directed against CSa-receptor is indicative of an autoimmune disease in said subject. Furthermore, the application relates to kits comprising C5a-receptor or an immunogenic fragment thereof and the use of CSa-receptor.

Abstract: The present invention relates to a method for diagnosis of a cancer, comprising the steps of (i) determining the level of antibodies against vascular endothelial growth factor (VEGF) in a sample from a subject to be diagnosed, (ii) comparing the determined level in the sample to a control level derived from subjects without cancer; wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative for cancer in the subject. Furthermore, the invention relates to method of predicting response and outcome of a treatment of a cancer with an angiogenesis inhibitor.